JP2004018490A - External preparation for skin for strengthening horny cell layer barrier - Google Patents
External preparation for skin for strengthening horny cell layer barrier Download PDFInfo
- Publication number
- JP2004018490A JP2004018490A JP2002178356A JP2002178356A JP2004018490A JP 2004018490 A JP2004018490 A JP 2004018490A JP 2002178356 A JP2002178356 A JP 2002178356A JP 2002178356 A JP2002178356 A JP 2002178356A JP 2004018490 A JP2004018490 A JP 2004018490A
- Authority
- JP
- Japan
- Prior art keywords
- area
- skin care
- skin
- keratinocytes
- cosmetic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000004888 barrier function Effects 0.000 title claims description 9
- 238000005728 strengthening Methods 0.000 title description 2
- 239000002537 cosmetic Substances 0.000 claims abstract description 40
- 229920000642 polymer Polymers 0.000 claims abstract description 16
- 150000001875 compounds Chemical class 0.000 claims abstract description 15
- 239000000178 monomer Substances 0.000 claims abstract description 14
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 10
- 239000000470 constituent Substances 0.000 claims abstract description 9
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 4
- 125000000539 amino acid group Chemical group 0.000 claims abstract description 4
- 210000002510 keratinocyte Anatomy 0.000 claims description 54
- 210000003491 skin Anatomy 0.000 claims description 42
- 150000003839 salts Chemical class 0.000 claims description 12
- FQYPKQOQUNFBDP-QMMMGPOBSA-N (2s)-6-amino-2-(2-methylprop-2-enoylamino)hexanoic acid Chemical compound CC(=C)C(=O)N[C@H](C(O)=O)CCCCN FQYPKQOQUNFBDP-QMMMGPOBSA-N 0.000 claims description 6
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 4
- 239000002390 adhesive tape Substances 0.000 claims description 3
- 125000004432 carbon atom Chemical group C* 0.000 claims description 3
- 210000004027 cell Anatomy 0.000 claims description 3
- 239000003623 enhancer Substances 0.000 claims description 3
- 230000037307 sensitive skin Effects 0.000 claims description 3
- 102000011782 Keratins Human genes 0.000 claims 1
- 108010076876 Keratins Proteins 0.000 claims 1
- 239000006210 lotion Substances 0.000 description 24
- 230000000694 effects Effects 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- -1 methacryloyl group Chemical group 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 238000011282 treatment Methods 0.000 description 7
- FHKSXSQHXQEMOK-UHFFFAOYSA-N hexane-1,2-diol Chemical compound CCCCC(O)CO FHKSXSQHXQEMOK-UHFFFAOYSA-N 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 238000003756 stirring Methods 0.000 description 5
- 210000000434 stratum corneum Anatomy 0.000 description 5
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 4
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 4
- 239000004472 Lysine Substances 0.000 description 4
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 4
- 239000002585 base Substances 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- ZXJXZNDDNMQXFV-UHFFFAOYSA-M crystal violet Chemical compound [Cl-].C1=CC(N(C)C)=CC=C1[C+](C=1C=CC(=CC=1)N(C)C)C1=CC=C(N(C)C)C=C1 ZXJXZNDDNMQXFV-UHFFFAOYSA-M 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 229960001235 gentian violet Drugs 0.000 description 4
- 235000011187 glycerol Nutrition 0.000 description 4
- 150000003431 steroids Chemical class 0.000 description 4
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 3
- 239000013589 supplement Substances 0.000 description 3
- FQOWJGGXNSRNJS-YFKPBYRVSA-N (2s)-2-(2-methylprop-2-enoylamino)propanoic acid Chemical compound OC(=O)[C@H](C)NC(=O)C(C)=C FQOWJGGXNSRNJS-YFKPBYRVSA-N 0.000 description 2
- OZAIFHULBGXAKX-UHFFFAOYSA-N 2-(2-cyanopropan-2-yldiazenyl)-2-methylpropanenitrile Chemical compound N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 2
- BOURDYMMTZXVRY-UHFFFAOYSA-N 2-(2-methylprop-2-enoylamino)acetic acid Chemical compound CC(=C)C(=O)NCC(O)=O BOURDYMMTZXVRY-UHFFFAOYSA-N 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- BAPJBEWLBFYGME-UHFFFAOYSA-N Methyl acrylate Chemical compound COC(=O)C=C BAPJBEWLBFYGME-UHFFFAOYSA-N 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000003020 moisturizing effect Effects 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- 230000000379 polymerizing effect Effects 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical class CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 description 1
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 1
- XPFCZYUVICHKDS-UHFFFAOYSA-N 3-methylbutane-1,3-diol Chemical compound CC(C)(O)CCO XPFCZYUVICHKDS-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- UIERETOOQGIECD-UHFFFAOYSA-N Angelic acid Natural products CC=C(C)C(O)=O UIERETOOQGIECD-UHFFFAOYSA-N 0.000 description 1
- 239000004342 Benzoyl peroxide Substances 0.000 description 1
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- IMROMDMJAWUWLK-UHFFFAOYSA-N Ethenol Chemical compound OC=C IMROMDMJAWUWLK-UHFFFAOYSA-N 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical class OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical class CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- HFBMWMNUJJDEQZ-UHFFFAOYSA-N acryloyl chloride Chemical compound ClC(=O)C=C HFBMWMNUJJDEQZ-UHFFFAOYSA-N 0.000 description 1
- 125000003647 acryloyl group Chemical group O=C([*])C([H])=C([H])[H] 0.000 description 1
- 150000001263 acyl chlorides Chemical class 0.000 description 1
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001447 alkali salts Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 125000005250 alkyl acrylate group Chemical group 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 239000002280 amphoteric surfactant Substances 0.000 description 1
- 239000003945 anionic surfactant Substances 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000019400 benzoyl peroxide Nutrition 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 239000003093 cationic surfactant Substances 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 238000009223 counseling Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
- OIKBVOIOVNEVJR-UHFFFAOYSA-N hexadecyl 6-methylheptanoate Chemical compound CCCCCCCCCCCCCCCCOC(=O)CCCCC(C)C OIKBVOIOVNEVJR-UHFFFAOYSA-N 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229940119170 jojoba wax Drugs 0.000 description 1
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000004200 microcrystalline wax Substances 0.000 description 1
- 235000019808 microcrystalline wax Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 229940055577 oleyl alcohol Drugs 0.000 description 1
- XMLQWXUVTXCDDL-UHFFFAOYSA-N oleyl alcohol Natural products CCCCCCC=CCCCCCCCCCCO XMLQWXUVTXCDDL-UHFFFAOYSA-N 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- WCVRQHFDJLLWFE-UHFFFAOYSA-N pentane-1,2-diol Chemical compound CCCC(O)CO WCVRQHFDJLLWFE-UHFFFAOYSA-N 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 229960005323 phenoxyethanol Drugs 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000003505 polymerization initiator Substances 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 229940069774 quince extract Drugs 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- 230000004215 skin function Effects 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 230000001360 synchronised effect Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 150000003625 trehaloses Chemical class 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
Images
Landscapes
- Cosmetics (AREA)
Abstract
Description
【０００１】
【発明の属する技術分野】
本発明は、角質細胞面積増大剤及びそれを含有するスキンケア化粧料に関する。
【０００２】
【従来の技術】
スキンケアは肌を美しく、清浄に保つための化粧料であって、古くは、油性成分の閉塞によって、荒れた肌からの水分散逸を防ぐような形態から始まっている。基本は、角質細胞の不順によって生じた、水分保持機能を如何に補完するかがこれまでの課題であり、ＮＭＦと呼ばれるアミノ酸類、ムコ多糖類を主とする保湿因子の補給、ＮＥＦと呼ばれる脂質を主とする閉塞保湿因子の補給、トレハロース、硫酸化トレハロースの塩、ヒアルロン酸の塩等の高抱水性成分の塗布による、角質細胞の機能不全を補完する方法が開発されている。又、角質細胞そのものへ働きかけて、肌を保全する方法として、フィトステサイドとステロイドを組み合わせて、角質細胞の交代周期を同調させる方法が開発されている。更に、機能不全を起こした角層から炎症性物質が侵入しないように、ポリメタクリロイルオキシエトキシホスホリルコリンなどの保護膜で防御する方法も開発されている。しかしながら、これらの方法の殆どは、フィトステサイドとステロイドの組合せを除いては、失われた機能の代替、補完という、対症的な対応であり、角層そのもの、言い換えれば角層の生理そのものを変えるものではない。又、フィトステサイドとステロイドの組合せについても、セルサイクルの同調と言うことから、効果発現までに要する期間が長い、或いは、化粧料では副作用の大きさ故に使用しにくいステロイドの使用が必須であるなどの欠点があり、実用的とは言い難い面があった。本来的には、皮膚機能の低下、肌荒れなどによって、角シル細胞の面積が矮小化する現象が認められていること、所謂「敏感肌」と言われる諸刺激に過敏な人においては、角質細胞の面積が平均に比して小さいこと等が既に知られていることから、角質細胞の面積を増大させる手段があれば、本質的なスキンケアにつながることは、化粧品に携わるものであれば誰もが気がついていることであったが、その様な手段が全く見出されていないのが現状であった。
【０００３】
一方、後記一般式（１）に表される化合物を構成モノマーの一つとするポリマーは、既に知られており、例えば、ポリ（Ｎ−メタクリロイルリシン）の様に化粧料用の原料として市販されているものもあるが（商品名「ＰＭリジン」；岐阜シェラック株式会社製）その作用としては、ダメージを受けた皮膚や毛髪のダメージ部である、ペプチドの切断面のアニオンサイトに吸着し、ダメージ部を保護する作用を有し、皮膚保護化粧料用素材として有用なことは既に知られていたが、ダメージを受けたり或いは先天的な原因で角質細胞面積が小さくなっていて、化学物質に過敏になっている人に投与した場合、角質細胞の面積を増大させ、以て角層強化によるバリア機能の向上をなし得ることは全く知られていないことであった。
【０００４】
更に、ポリ（Ｎ−メタクリロイルリシン）等の一般式（１）に表される化合物を構成モノマーの一つとするポリマーを含有する、角層バリア機能向上用のスキンケア化粧料は全く知られていない。
【０００５】
【化２】
（但し、式中Ｒ１は水素原子又は炭素数１〜４のアルキル基を表し、Ａはアミノ酸残基を表す。）
【０００６】
【発明が解決しようとする課題】
本発明は、この様な状況下為されたものであり、角質細胞の面積を増大させ、本質的なスキンケアを具現化する手段を提供することを課題とする。
【０００７】
【課題の解決手段】
この様な状況に鑑みて、本発明者らは、角質細胞の面積を増大させ、本質的なスキンケアを具現化する手段を求めて、鋭意研究努力を重ねた結果、一般式（１）に表される化合物を構成モノマーの一つとするポリマーを化粧料に含有させて投与すると、角質細胞面積を増大させる作用を発揮することを見出し、発明を完成させるに至った。即ち、本発明は以下に示す技術に関するものである。
（１）上記一般式（１）に表される化合物を、構成モノマーの少なくとも１つとする、ポリマーからなる角質細胞面積増大剤。
（２）一般式（１）に表される化合物を、構成モノマーの少なくとも１つとする、ポリマーが、ポリ（Ｎ−メタクリロイルリシン）及び／又はその塩であることを特徴とする、（１）に記載の角質細胞面積増大剤。
（３）（１）又は（２）に記載の角質細胞面積増大剤を含有する、スキンケア化粧料。
（４）角層バリア機能向上用であることを特徴とする、（３）に記載のスキンケア化粧料。
（５）角質細胞を、粘着テープにより採取し、角質細胞面積を測定し、標準値より小さい人に適用されることを特徴とする、（３）又は（４）に記載のスキンケア化粧料。
（６）敏感肌用であることを特徴とする、（３）〜（５）何れか１項に記載の化粧料。
以下、本発明について更に詳細に説明を加える。
【０００８】
【発明の実施の形態】
（１）本発明の角質細胞面積増大剤
本発明の角質細胞面積増大剤は、上記一般式（１）に表される化合物を構成モノマーの一つとすることを特徴とする。一般式（１）に於いて、Ｒ１は水素原子又は炭素数１〜４のアルキル基を表し、好ましくは水素原子又はメチル基である。言い換えれば、一般式（１）に於けるＡに表される基を除く部分としては、アクリロイル基又はメタクロイル基が特に好ましい。Ａで表される基としては通常知られているアミノ酸の残基であれば特段の限定はなく、例えば、リシン残基、アルギニン残基、ロイシン残基、グリシン残基、アラニン残基などが好ましく例示でき、中でもリシン残基が特に好ましい。又、ポリマーとしては一般式（１）表される化合物以外に以外に、通常知られているモノマー類、例えば、ビニルアルコール、スチレン、アクリル酸、アクリル酸メチル、メタクリル酸、メタクリル酸メチルなどをともに用いてコポリマーにすることもできる。好ましい形態は、一般式（１）の化合物の総量の１割以下に他のモノマーを抑えることであり、一般式（１）に表される化合物のみを重合して得られるポリマーが特に好ましい。一般式（１）に表される化合物も唯一種のみを用いることが特に好ましい。かかる一般式（１）に表される化合物は、アミノ酸とアクリロイルクロリド等の対応するアシルクロリドとを縮合することにより得ることができる。かかるポリマーは、常法に従ってこれらのモノマーを重合し製造することができる。例えば、モノマーを溶媒中でアゾビスイソブチロニトリルや過酸化ベンゾイルなどの重合開始剤とともに加熱処理することにより製造することができる。かくして得られたポリマーはそのまま使用することもできるし、酸或いはアルカリとともに塩として使用することもできる。塩としては、通常知られているものであれば特段の限定無く使用することができ、例えば、アルカリ塩としては、ナトリウム塩、カリウム塩等のアルカリ金属塩、カルシウム、マグネシウム等のアルカリ土類金属塩、アンモニウム塩、トリエタノールアミン塩、トリエチルアミン塩等の有機アミン塩類、リジン塩、アルギニン塩等の塩基性アミノ酸塩等が好ましく例示できる。又、酸の塩としては、塩酸塩、硝酸塩、硫酸塩、リン酸塩などの鉱酸塩、クエン酸塩、蓚酸塩、酢酸塩等の有機酸塩、炭酸塩等が好ましく例示できる。かくして得られた、一般式（１）に表される化合物を構成モノマーの一つとする及び／又はその塩は、皮膚外用で皮膚に投与すると、標準より面積の小さい角質細胞に対して作用し、その面積を増大させる作用を発揮させる。これにより、角層に於ける角質細胞の密集性が高まり、角質細胞が小さくなっていたが故に低下していたバリア機能を回復することができる。これが本発明の角質細胞面積増大剤の作用である。本発明のスキンケア化粧料に於ける、かかる角質細胞面積増大剤の好ましい含有量は、化粧料全量に対して。総量で０．０１〜１０重量％であり、更に好ましくは、０．１〜５重量％である。
【０００９】
（２）本発明のスキンケア化粧料
本発明のスキンケア化粧料は、上記一般式（１）に表されるポリマー及び／又はその塩を含有することを特徴とする。本発明のスキンケア化粧料は、角質細胞面積が小さくなり、これによって角層バリア能が低下し、肌が過敏になっている人に投与し、角質細胞の面積を増大させ、これにより、角層に於ける角質細胞の密集性が高まり、角質細胞が小さくなっていたが故に低下していたバリア機能を回復する為に用いることが好ましい。角質細胞面積については、多くのカウンセリング販売に於いて測定されている項目であり、その様な技術を応用することにより測定することができる。この様な技術としては、例えば、顔の頬などの部位より粘着テープなどを用いて、ストリッピングにより角質細胞を採取し、ゲンチアナバイオレット等の染色剤を用いて、角質細胞を染色し、角質細胞の境界を明確にし、角質細胞の面積を測定する技術が例示できる。この様な測定に於いて、平均５００μｍ２を割り込むような人に本発明のスキンケア化粧料を適用することが好ましい。即ち、本発明のスキンケア化粧料は次にステップで選択された人に使用されることが好ましい。
（１）皮膚より角質細胞を採取する。
（２）前記角質細胞の面積を測定する。
（３）平均的な角質細胞面積と比較する。簡易的には平均面積として５００μｍ２を用いる。
（４）角質細胞面積が小さいと判定された人を本発明のスキンケア化粧料の対象者とする。
【００１０】
本発明のスキンケア化粧料としては、通常スキンケア化粧料で使用されている剤形のものであれば特段の限定無く使用することができる。例えば、化粧水、エッセンス、フォーム状パック、ピールオフパック、乳液、クリーム、ジェル等が好ましく例示できる。又、本発明のスキンケア化粧料に於いては、通常化粧料で使用される任意成分を含有することができる。この様な任意成分としては、例えば、ワセリンやマイクロクリスタリンワックス等のような炭化水素類、ホホバ油やセチルイソオクタネート等のエステル類、オリーブ油等のトリグリセライド類、オクタデシルアルコールやオレイルアルコール等の高級アルコール類、グリセリンや１，３−ブタンジオール、１，２−ペンタンジオール、イソプレングリコール、ジプロピレングリコール、１，２−ヘキシレングリコール等の多価アルコール類、非イオン界面活性剤、アニオン界面活性剤、カチオン界面活性剤、両性界面活性剤、エタノール、カーボポール等の増粘剤、防腐剤、紫外線吸収剤、抗酸化剤類等が例示できる。これらの内、好ましい形態としては、１，２−ヘキシレングリコールを４〜１０重量％含有する形態及び／又はフェノキシエタノールを０．２〜１重量％含有する形態が例示できる。又、従来より知られているポリメタクリロイルオキシエトキシホスソリルコリン等の角層バリア機能補強剤、ＮＭＦ、ＮＥＦと言ったスキンケア成分を含むことも好ましい。本発明のスキンケア化粧料は、必須成分と任意の成分とを常法に従って処理することにより、製造することができる。
【００１１】
【実施例】
以下に実施例を挙げて、本発明について更に詳細に説明を加えるが、本発明がかかる実施例にのみ限定されないことは言うまでもない。
【００１２】
＜実施例１＞
以下に示す処方に従って、本発明のスキンケア化粧料である化粧水（ローション）を作成した。即ち、処方成分を９０℃で加熱攪拌可溶化し、攪拌冷却し、ローション（ＰＭＬローション）を得た。同時にポリ（Ｎ−メタクリロイルリシン）（「ＰＭリジン」）を水に置換した比較例のローション（ベースローション）を作成し、パネラー１群１０名計２０名を用いて使用テストを行った。使用テスト開始直前にパネラーの頬部よりテープストリッピングにより角質細胞を採取し、ゲンチアナバイオレットで染色し平均面積を測定した。１群はＰＭＬローションで、もう１群はベースローションで、１日朝晩２回処置し、これを１ヶ月間続けた。最後の処置の２４時間後に再度角質細胞面積を測定し、（処置後の面積）／（処置前の面積）で面積変化率を求めた。この結果は図１に示す。これより、本発明の化粧料で処置した群は有意に角質細胞の面積が増加していることがわかる。これより、本発明の角質細胞面積増大剤である、ポリ（Ｎ−メタクリロイルリシン）の作用が証明された。
（ＰＭＬローション処方）
「ＰＭリジン」 １ 重量部
グリセリン ３ 重量部
１，２−ヘキシレングリコール ５ 重量部
エタノール ５ 重量部
水 ８６ 重量部
【００１３】
＜実施例２＞
実施例１のＰＭＬローションとベースローションを用いて、角質細胞面積の小さい人を対象に、１ヶ月間の使用テストを行った。即ち、パネラー候補者４０名を集め、角質細胞の面積を測定し、５００μｍ以下の人１４名を選別した。バラツキの無いようにこの１４名を７人づつの２群に分け、１群はＰＭＬローションで、もう１群はベースローションで、１日朝晩２回処置し、これを１ヶ月間続けた。その後、化粧料による肌の調子の改善度を、スコア５：明瞭に改善、スコア４：やや改善、スコア３：改善せず、スコア２：やや悪化、スコア１：明瞭に悪化の基準で判定してもらった。判定結果を出現例数として、表１に示す。これより、本発明のスキンケア化粧料である、ＰＭＬローションが角質細胞面積の小さい人に優れた効果をもたらすことがわかる。
【００１４】
【表１】
＜実施例３＞
実施例２と同様に５００μｍ以上の人３０名を用いて同様に検討を行ったが、角質細胞面積の小さい人ほどは効果の差が見られなかった。
【００１６】
【表２】
＜実施例４＞
以下に示す処方に従って、本発明のスキンケア化粧料である化粧水（ローション）を作成した。即ち、処方成分を９０℃で加熱攪拌可溶化し、攪拌冷却し、ローション（ＰＭＧローション）を得た。パネラー１群１０名を用いて使用テストを行った。使用テスト開始直前にパネラーの頬部よりテープストリッピングにより角質細胞を採取し、ゲンチアナバイオレットで染色し平均面積を測定した。（処置後の面積）／（処置前の面積）で表される面積変化率は１．０３であり、ポリ（Ｎ−メタクリロイルグリシン）の角質細胞面積増大作用が確認された。
（ＰＭＧローション処方）
ポリ（Ｎ−メタクリロイルグリシン） １ 重量部
グリセリン ３ 重量部
１，２−ヘキシレングリコール ５ 重量部
エタノール ５ 重量部
水 ８６ 重量部
【００１８】
＜実施例５＞
以下に示す処方に従って、本発明のスキンケア化粧料である化粧水（ローション）を作成した。即ち、処方成分を９０℃で加熱攪拌可溶化し、攪拌冷却し、ローション（ＰＭＡローション）を得た。パネラー１群１０名を用いて使用テストを行った。使用テスト開始直前にパネラーの頬部よりテープストリッピングにより角質細胞を採取し、ゲンチアナバイオレットで染色し平均面積を測定した。（処置後の面積−処置前の面積）／処置後の面積で表される面積変化率は１．０３であり、ポリ（Ｎ−メタクリロイルアラニン）の角質細胞面積増大作用が確認された。
（ＰＭＧローション処方）
ポリ（Ｎ−メタクリロイルアラニン） １ 重量部
グリセリン ３ 重量部
１，２−ヘキシレングリコール ５ 重量部
エタノール ５ 重量部
水 ８６ 重量部
【００１９】
＜実施例６＞
以下に示す処方に従って、本発明のスキンケア化粧料を作成した。即ち、イ、ロの成分を８０℃で加熱し、イに徐々にロを加えて中和して、攪拌冷却して、エッセンスを得た。
イ
カルボキシビニルポリマー１％水溶液 ６ 重量部
カーボポール１３８２の１％水溶液 ５ 重量部
（アクリル酸・メタクリル酸（Ｃ１０−３０）アルキル）
マルメロエキス ０．１重量部
１，３−ブタンジオール ３ 重量部
１，２−ヘキシレングリコール ３ 重量部
「ＰＭリジン」 ２ 重量部
水 ７５．４重量部
ロ
水酸化カリウム１０％水溶液 ５．５重量部
【００２０】
【発明の効果】
本発明によれば、角質細胞の面積を増大させ、本質的なスキンケアを具現化する手段を提供することができる。
【図面の簡単な説明】
【図１】実施例１の結果を示す図である。[0001]
TECHNICAL FIELD OF THE INVENTION
The present invention relates to a keratinocyte area increasing agent and a skin care cosmetic containing the same.
[0002]
[Prior art]
Skin care is a cosmetic that keeps the skin beautiful and clean. In the old days, skin care began with a form that prevented water from dissipating from rough skin due to blockage of oily components. Basically, how to supplement the water retention function caused by irregularities in the keratinocytes has been a challenge so far, such as supplementation of amino acids called NMF, moisturizing factors mainly composed of mucopolysaccharides, and lipids called NEF A method has been developed to supplement the dysfunction of keratinocytes by replenishment of occlusive moisturizing factors, mainly by applying trehalose, salts of sulfated trehalose, salts of hyaluronic acid, etc. As a method of preserving the skin by acting on the keratinocytes themselves, a method has been developed in which phytosteside and steroids are combined to synchronize the alternation cycle of the keratinocytes. Further, a method has been developed in which a protective film such as polymethacryloyloxyethoxyphosphorylcholine is used to protect the inflammatory substance from entering the malfunctioning stratum corneum. However, most of these methods, except for the combination of phytosteide and steroids, are symptomatic treatments that replace or supplement the lost functions. It does not change. Also, for the combination of phytosteide and steroid, it is essential to use a steroid that is difficult to use due to the long period required for the effect to be exhibited or the side effect of cosmetics because of the fact that the cell cycle is synchronized. There are drawbacks, such as the fact that it is not practical. Originally, it has been observed that the area of keratinocytes is dwarfed due to decreased skin function and rough skin. In people who are hypersensitive to various stimuli called "sensitive skin", keratinocytes It is already known that the area of keratinocytes is smaller than the average, so if there is a means to increase the area of keratinocytes, it will lead to essential skin care if anyone involved in cosmetics However, at present, such a means has not been found at all.
[0003]
On the other hand, a polymer containing a compound represented by the following general formula (1) as one of constituent monomers is already known, and is commercially available as a raw material for cosmetics such as poly (N-methacryloyl lysine). There are also products (trade name "PM lysine"; manufactured by Gifu Shellac Co., Ltd.) whose function is to adsorb to the anion site on the cut surface of the peptide, which is the damaged part of the damaged skin or hair, Has been known to have the effect of protecting skin, and is useful as a material for skin protective cosmetics. It has not been known at all that when administered to a subject, the area of keratinocytes can be increased, and thereby the barrier function can be improved by strengthening the stratum corneum.
[0004]
Furthermore, there is no known skin care cosmetic for improving the horny layer barrier function, which contains a polymer having a compound represented by the general formula (1) such as poly (N-methacryloyl lysine) as one of the constituent monomers.
[0005]
Embedded image
(In the formula, R1 represents a hydrogen atom or an alkyl group having 1 to 4 carbon atoms, and A represents an amino acid residue.)
[0006]
[Problems to be solved by the invention]
The present invention has been made under such circumstances, and has as its object to provide a means for increasing the area of keratinocytes and realizing essential skin care.
[0007]
[Means for solving the problem]
In view of such a situation, the present inventors have conducted intensive research efforts to find a means for increasing the area of keratinocytes and realizing essential skin care. It has been found that when a polymer containing the compound as one of the constituent monomers is added to a cosmetic and administered, the compound exerts an action of increasing the area of the keratinocyte, thereby completing the invention. That is, the present invention relates to the following technology.
(1) A keratinocyte area enhancer comprising a polymer, wherein the compound represented by the general formula (1) is at least one of the constituent monomers.
(2) The compound according to (1), wherein the polymer represented by the general formula (1) is at least one of the constituent monomers, and the polymer is poly (N-methacryloyl lysine) and / or a salt thereof. The keratinocyte area increasing agent according to the above.
(3) A skin care cosmetic comprising the keratinocyte area-enhancing agent according to (1) or (2).
(4) The skin care cosmetic according to (3), which is for improving a stratum corneum barrier function.
(5) The skin care cosmetic according to (3) or (4), wherein the keratinocytes are collected with an adhesive tape, the keratinocyte area is measured, and the keratinocytes are applied to a person smaller than a standard value.
(6) The cosmetic according to any one of (3) to (5), which is used for sensitive skin.
Hereinafter, the present invention will be described in more detail.
[0008]
BEST MODE FOR CARRYING OUT THE INVENTION
(1) The keratinocyte area increasing agent of the present invention is characterized in that the compound represented by the above general formula (1) is one of the constituent monomers. In the general formula (1), R1 represents a hydrogen atom or an alkyl group having 1 to 4 carbon atoms, preferably a hydrogen atom or a methyl group. In other words, as the portion excluding the group represented by A in the general formula (1), an acryloyl group or a methacryloyl group is particularly preferable. The group represented by A is not particularly limited as long as it is a commonly known amino acid residue. For example, lysine residue, arginine residue, leucine residue, glycine residue, alanine residue and the like are preferable. A lysine residue is particularly preferable. As the polymer, other than the compound represented by the general formula (1), commonly known monomers such as vinyl alcohol, styrene, acrylic acid, methyl acrylate, methacrylic acid, and methyl methacrylate may be used together. Can be used to form a copolymer. A preferred embodiment is to suppress other monomers to 10% or less of the total amount of the compound of the general formula (1), and a polymer obtained by polymerizing only the compound represented by the general formula (1) is particularly preferable. It is particularly preferable to use only one kind of the compound represented by the general formula (1). The compound represented by the general formula (1) can be obtained by condensing an amino acid with a corresponding acyl chloride such as acryloyl chloride. Such a polymer can be produced by polymerizing these monomers according to a conventional method. For example, it can be produced by heating a monomer together with a polymerization initiator such as azobisisobutyronitrile and benzoyl peroxide in a solvent. The polymer thus obtained can be used as it is, or can be used as a salt together with an acid or alkali. As the salt, any known salt can be used without any particular limitation. For example, as an alkali salt, an alkali metal salt such as a sodium salt or a potassium salt, or an alkaline earth metal such as calcium or magnesium can be used. Organic amine salts such as salts, ammonium salts, triethanolamine salts and triethylamine salts, and basic amino acid salts such as lysine salts and arginine salts are preferred. Preferred examples of the acid salt include mineral salts such as hydrochloride, nitrate, sulfate and phosphate; organic acid salts such as citrate, oxalate and acetate; and carbonates. The thus obtained compound represented by the general formula (1) as one of the constituent monomers and / or a salt thereof, when administered externally to the skin, acts on keratinocytes having a smaller area than the standard, The effect of increasing the area is exhibited. As a result, the density of keratinocytes in the stratum corneum is increased, and the barrier function that has been reduced due to the reduced keratinocytes can be recovered. This is the action of the keratinocyte area increasing agent of the present invention. In the skin care cosmetic of the present invention, the preferable content of the keratinocyte area-enhancing agent is based on the total amount of the cosmetic. The total amount is 0.01 to 10% by weight, and more preferably 0.1 to 5% by weight.
[0009]
(2) Skin care cosmetic of the present invention The skin care cosmetic of the present invention is characterized by containing the polymer represented by the general formula (1) and / or a salt thereof. The skin care cosmetic composition of the present invention reduces the area of the keratinous cells, thereby reducing the horny layer barrier ability, and administers it to a person with hypersensitive skin to increase the area of the horny cells, thereby It is preferable to use the method in order to increase the density of keratinocytes and to restore the barrier function which has been reduced because the keratinocytes have become smaller. The keratinocyte area is an item measured in many counseling sales, and can be measured by applying such a technique. As such a technique, for example, keratinocytes are collected by stripping from a site such as the cheek of the face using an adhesive tape and the like, and keratinocytes are stained using a stain such as gentian violet, and the keratinocytes are stained. Can be exemplified by clarifying the boundary of and measuring the area of the keratinocyte. In such a measurement, it is preferable to apply the skin care cosmetic of the present invention to a person who cuts the average of 500 μm 2. That is, it is preferable that the skin care cosmetic of the present invention is used for the person selected in the next step.
(1) Collect keratinocytes from skin.
(2) The area of the keratinocytes is measured.
(3) Compare with the average keratinocyte area. For simplicity, an average area of 500 μm 2 is used.
(4) A person determined to have a small keratinocyte area is a subject of the skin care cosmetic of the present invention.
[0010]
The skin care cosmetic of the present invention can be used without any particular limitation as long as it has a dosage form usually used in skin care cosmetics. For example, a lotion, an essence, a foam pack, a peel-off pack, a milky lotion, a cream, a gel and the like can be preferably exemplified. In addition, the skin care cosmetic of the present invention can contain optional components usually used in cosmetics. Such optional components include, for example, hydrocarbons such as petrolatum and microcrystalline wax, esters such as jojoba oil and cetyl isooctanoate, triglycerides such as olive oil, and higher alcohols such as octadecyl alcohol and oleyl alcohol. , Glycerin, 1,3-butanediol, 1,2-pentanediol, polyhydric alcohols such as isoprene glycol, dipropylene glycol, 1,2-hexylene glycol, nonionic surfactants, anionic surfactants, Examples thereof include cationic surfactants, amphoteric surfactants, thickeners such as ethanol and carbopol, preservatives, ultraviolet absorbers, and antioxidants. Of these, preferred examples include a form containing 4 to 10% by weight of 1,2-hexylene glycol and / or a form containing 0.2 to 1% by weight of phenoxyethanol. It is also preferable to include a conventionally known stratum corneum barrier function enhancer such as polymethacryloyloxyethoxyphosphorylcholine, and skin care ingredients such as NMF and NEF. The skin care cosmetic of the present invention can be produced by treating essential components and optional components according to a conventional method.
[0011]
【Example】
Hereinafter, the present invention will be described in more detail with reference to Examples, but it is needless to say that the present invention is not limited to only these Examples.
[0012]
<Example 1>
According to the following formulation, a lotion, which is a skin care cosmetic of the present invention, was prepared. That is, the formulation components were heated and solubilized at 90 ° C., stirred, and cooled to obtain a lotion (PML lotion). At the same time, a lotion (base lotion) of a comparative example in which poly (N-methacryloyl lysine) ("PM lysine") was replaced with water was prepared, and a usage test was conducted using 10 panelists per group and 20 persons in total. Immediately before the start of the use test, keratinocytes were collected from the cheeks of the panel by tape stripping, stained with gentian violet, and the average area was measured. One group was treated with PML lotion and the other with base lotion, twice a day, morning and evening, and continued for one month. Twenty-four hours after the last treatment, the keratinocyte area was measured again, and the area change rate was determined by (area after treatment) / (area before treatment). The result is shown in FIG. This indicates that the group treated with the cosmetic of the present invention has a significantly increased keratinocyte area. Thus, the action of poly (N-methacryloyl lysine), which is the keratinocyte area increasing agent of the present invention, was proved.
(PML lotion prescription)
"PM lysine" 1 part by weight glycerin 3 parts by
<Example 2>
Using the PML lotion and the base lotion of Example 1, a one-month use test was performed on a person having a small keratinocyte area. That is, 40 panelist candidates were collected, the area of keratinocytes was measured, and 14 persons with a size of 500 μm or less were selected. The 14 patients were divided into two groups of 7 without variation, one group was treated with PML lotion, and the other group was treated with base lotion twice a day, morning and evening, and continued for one month. Thereafter, the degree of improvement of the skin condition by the cosmetic was determined based on the criteria of score 5: clearly improved, score 4: slightly improved, score 3: not improved, score 2: slightly deteriorated, score 1: clearly deteriorated. I got it. Table 1 shows the determination result as the number of appearance cases. This shows that the PML lotion, which is the skin care cosmetic of the present invention, has an excellent effect on people with a small keratinocyte area.
[0014]
[Table 1]
<Example 3>
Similar examination was conducted using 30 persons of 500 μm or more in the same manner as in Example 2, but no difference in the effect was observed in persons having a smaller keratinocyte area.
[0016]
[Table 2]
<Example 4>
According to the following formulation, a lotion, which is a skin care cosmetic of the present invention, was prepared. That is, the prescription components were solubilized by heating at 90 ° C. with stirring, cooled with stirring, and a lotion (PMG lotion) was obtained. A usage test was performed using 10 panelists per group. Immediately before the start of the use test, keratinocytes were collected from the cheeks of the panel by tape stripping, stained with gentian violet, and the average area was measured. The area change rate represented by (area after treatment) / (area before treatment) was 1.03, confirming the effect of poly (N-methacryloylglycine) on increasing the area of keratinocytes.
(PMG lotion prescription)
Poly (N-methacryloylglycine) 1 part by weight Glycerin 3 parts by
<Example 5>
According to the following formula, a lotion (lotion), which is a skin care cosmetic of the present invention, was prepared. That is, the prescription components were solubilized by heating at 90 ° C. with stirring, cooled with stirring, and a lotion (PMA lotion) was obtained. A usage test was performed using 10 panelists per group. Immediately before the start of the use test, keratinocytes were collected from the cheeks of the panel by tape stripping, stained with gentian violet, and the average area was measured. The area change rate represented by (area after treatment-area before treatment) / area after treatment was 1.03, confirming the effect of poly (N-methacryloylalanine) on increasing the area of keratinocytes.
(PMG lotion prescription)
Poly (N-methacryloylalanine) 1 part by weight Glycerin 3 parts by
<Example 6>
The skin care cosmetic of the present invention was prepared according to the following formulation. That is, the components (a) and (b) were heated at 80 ° C., and (b) was gradually added to the mixture to neutralize it, followed by stirring and cooling to obtain an essence.
Quince extract 0.1 part by
【The invention's effect】
According to the present invention, it is possible to provide a means for increasing the area of keratinocytes and realizing essential skin care.
[Brief description of the drawings]
FIG. 1 is a diagram showing the results of Example 1.
Claims (6)
（但し、式中Ｒ１は水素原子又は炭素数１〜４のアルキル基を表し、Ａはアミノ酸残基を表す。）An agent for increasing a keratinocyte area comprising a polymer, wherein the compound represented by the following general formula (1) is at least one of constituent monomers.
(In the formula, R1 represents a hydrogen atom or an alkyl group having 1 to 4 carbon atoms, and A represents an amino acid residue.)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2002178356A JP2004018490A (en) | 2002-06-19 | 2002-06-19 | External preparation for skin for strengthening horny cell layer barrier |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2002178356A JP2004018490A (en) | 2002-06-19 | 2002-06-19 | External preparation for skin for strengthening horny cell layer barrier |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007213276A Division JP2007302699A (en) | 2007-08-20 | 2007-08-20 | Agent for increasing area of corneocyte and skin-care cosmetic containing the same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004018490A true JP2004018490A (en) | 2004-01-22 |
| JP2004018490A5 JP2004018490A5 (en) | 2005-04-07 |
Family
ID=31176100
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002178356A Pending JP2004018490A (en) | 2002-06-19 | 2002-06-19 | External preparation for skin for strengthening horny cell layer barrier |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP2004018490A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1657263A4 (en) * | 2003-07-18 | 2007-02-14 | Japan Exlan Co Ltd | Polymer sustainedly releasing amino acid derivative, cosmetic and fiber construct containing the polymer, method of producing the same and method of regenerating the same |
| JP2007153811A (en) * | 2005-12-06 | 2007-06-21 | Pola Chem Ind Inc | External preparation for skin for improving skin barrier function |
| JP2014034546A (en) * | 2012-08-09 | 2014-02-24 | Pola Chem Ind Inc | External preparation for skin |
| CN113470764A (en) * | 2021-07-13 | 2021-10-01 | 广东丸美生物技术股份有限公司 | Blending method and device for cosmetic formula |
-
2002
- 2002-06-19 JP JP2002178356A patent/JP2004018490A/en active Pending
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1657263A4 (en) * | 2003-07-18 | 2007-02-14 | Japan Exlan Co Ltd | Polymer sustainedly releasing amino acid derivative, cosmetic and fiber construct containing the polymer, method of producing the same and method of regenerating the same |
| JP2007153811A (en) * | 2005-12-06 | 2007-06-21 | Pola Chem Ind Inc | External preparation for skin for improving skin barrier function |
| JP2014034546A (en) * | 2012-08-09 | 2014-02-24 | Pola Chem Ind Inc | External preparation for skin |
| CN113470764A (en) * | 2021-07-13 | 2021-10-01 | 广东丸美生物技术股份有限公司 | Blending method and device for cosmetic formula |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPH10513452A (en) | Formulations and methods for reducing skin irritation | |
| JPH08225427A (en) | Composition for make-up or dermatology containing mixture ofceramide and its use for giving dampness to skin | |
| JP5978059B2 (en) | Skin preparation | |
| WO2013018884A1 (en) | Keratotic plug regrowth inhibition agent, keratotic plug regrowth inhibition method, and keratotic plug regrowth inhibition kit | |
| AU666641B2 (en) | Gel type compositions having improved oil control | |
| JP2006527166A (en) | Skin care composition containing skin lightening agent | |
| JP3084086B2 (en) | Keratin plug regeneration inhibitor | |
| KR20180012721A (en) | Cosmetic Composition for Lip Anti-aging Comprising Tocopheryl Acetate as an Effective Ingredient | |
| JP4394869B2 (en) | Topical skin preparation | |
| CA2455231C (en) | Topical composition for follicular delivery of an ornithine decarboxylase inhibitor | |
| JP2004018490A (en) | External preparation for skin for strengthening horny cell layer barrier | |
| US20030215413A1 (en) | Compositions containing stabilized retinoid | |
| EP3466406A1 (en) | Anti-wrinkle cosmetic composition, composition system and method for cosmetic skin treatment | |
| JP5400196B2 (en) | Square plug regeneration inhibitor | |
| WO2015007567A1 (en) | Cosmetic composition comprising a cucurbic acid compound and an amino acid-based anionic surfactant | |
| JP2881333B2 (en) | Whitening cosmetics | |
| JP2004107210A (en) | Skin care preparation for external use | |
| EP3501493A1 (en) | Cosmetic anti-blemish composition, use of the composition, anti-blemish treatment method and application device | |
| KR102029652B1 (en) | Cosmetic composition for exfoliation | |
| US11478409B2 (en) | Anti-wrinkle cosmetic composition, composition system and method for cosmetic skin treatment | |
| JP4049414B2 (en) | Emulsified composition | |
| JP3390868B2 (en) | Cosmetic and its use | |
| JPH11180851A (en) | Skin cosmetic | |
| JP2007302699A (en) | Agent for increasing area of corneocyte and skin-care cosmetic containing the same | |
| JP2010143884A (en) | Chapped skin improving agent |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Written amendment |
Effective date: 20040521 Free format text: JAPANESE INTERMEDIATE CODE: A523 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20040521 |
|
| RD03 | Notification of appointment of power of attorney |
Effective date: 20040521 Free format text: JAPANESE INTERMEDIATE CODE: A7423 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20050223 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20050308 |
|
| A521 | Written amendment |
Effective date: 20050425 Free format text: JAPANESE INTERMEDIATE CODE: A523 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20070619 |
|
| A02 | Decision of refusal |
Effective date: 20071106 Free format text: JAPANESE INTERMEDIATE CODE: A02 |